Compare NSRX & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NSRX | GRML |
|---|---|---|
| Founded | 2019 | N/A |
| Country | Israel | United States |
| Employees | 7 | 5 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 34.9M |
| IPO Year | N/A | 2022 |
| Metric | NSRX | GRML |
|---|---|---|
| Price | $3.08 | $0.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | 20.6K | ★ 3.4M |
| Earning Date | 03-25-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $0.21 |
| 52 Week High | $9.99 | $0.55 |
| Indicator | NSRX | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 42.58 |
| Support Level | $2.78 | $0.21 |
| Resistance Level | $3.58 | $0.34 |
| Average True Range (ATR) | 0.22 | 0.03 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 0.00 | 41.41 |
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.